Bristol Myers Squibb is licensing global rights to a Philochem program in development for both diagnostic imaging and targeted treatment of prostate cancer. It follows the pharma giant’s entry ...

Bristol Myers Squibb (BMY) closed the most recent trading day at $48.79, moving +1.06% from the previous trading session.

Looking into the current session, Bristol-Myers Squibb Inc. BMY shares are trading at $47.05, after a 1.20% decrease. Over the past month, the stock decreased by 6.76%, but over the past year, it ...

Bristol-Myers Squibb Company (NYSE:BMY) just reported healthy earnings but the stock price didn't move much. We think that investors have missed some encouraging factors underlying the profit figures.

Bristol Myers Squibb to acquire 2seventy Bio for $5.00 per share in a $286 million all-cash deal, an 88% premium to its last close. Expected to close in Q2 2025.

Since the initiation of their strategic neuroscience collaboration in December 2016, Evotec and Bristol Myers Squibb have been working together to identify disease-modifying treatments for a broad ...

Bristol Myers Squibb on Thursday said it will slash $2 billion in costs by the end of 2027, expanding its ongoing cost-savings effort to chart a path toward long-term growth. Stream San Diego News ...

FDA approves Bristol Myers Squibb's schizophrenia drug, the first new type of treatment in decades The twice-daily pill, Cobenfy, is a badly needed new treatment option for the nearly 3 million ...

Bristol-Myers Squibb's stock climbed as much as 11% on Friday, its biggest intraday surge since 2008, after beating profit forecasts and raising full-year guidance.

Bristol Myers Squibb said its trial evaluating a combination of cancer treatments failed to meet its primary endpoint.

Neither Bristol Myers Squibb nor RayzeBio undertakes any obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise, except to ...